Europe Non-Invasive Prenatal Testing (NIPT) Market to Grow with a CAGR of 14.06% through 2030
Growing
awareness about early fetal genetic screening and increasing adoption of
advanced genomic technologies in prenatal care, is expected to
drive the Europe Non-Invasive Prenatal Testing (NIPT) Market growth in the
forecast period, 2026-2030
According to
TechSci Research report, “Europe Non-Invasive Prenatal Testing (NIPT) Market
– By Country, Competition, Forecast & Opportunities, 2030F”, the Europe
Non-Invasive Prenatal Testing (NIPT) Market was valued at USD 868.11 Million in
2024 and is expected to reach USD 1914.06 Million by 2030 with a CAGR of 14.06%. The Europe Non-Invasive Prenatal
Testing (NIPT) market is gaining traction due to increasing healthcare
digitization and the growing demand for early and safe prenatal screening
methods. A rising focus on fetal health monitoring is encouraging the
integration of NIPT as a routine part of prenatal care. Healthcare providers
are actively incorporating NIPT into their diagnostic pathways to reduce
uncertainty and improve pregnancy outcomes. The convenience and efficiency of
the testing process, requiring only a maternal blood sample, has led to its
wider adoption across both public and private healthcare institutions. Rising
disposable incomes and an increased willingness among parents to invest in
advanced prenatal diagnostics are also contributing to market expansion.
Emerging
technologies such as next-generation sequencing (NGS) and cell-free DNA
analysis are pushing the boundaries of what NIPT can offer. These technologies
are making it possible to detect a wider range of chromosomal and
sub-chromosomal conditions with high sensitivity. Growing investment in
genomics research by European biotech firms and diagnostic startups is driving
innovation in test development. The market is also seeing a trend toward
digital health integration, where NIPT services are linked with mobile
applications and digital platforms for appointment scheduling, result delivery,
and follow-up consultations, enhancing patient engagement and satisfaction.
Significant
growth opportunities lie in expanding access to NIPT services through public
health programs and insurance coverage. Government-funded screening initiatives
targeting low- and middle-income populations can bridge the accessibility gap
and drive volume uptake. There is strong potential for developing low-cost NIPT
solutions tailored to price-sensitive markets without compromising test
accuracy. Cross-border collaborations between diagnostic laboratories and
academic institutions can accelerate clinical validation and regulatory
approval of novel tests. Growing demand for reproductive genetic counseling
alongside testing services also presents an avenue for integrated care
offerings. As awareness and acceptance of genetic screening continue to rise,
the market is well-positioned to benefit from both technological and service
delivery innovations.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Europe Non-Invasive Prenatal Testing (NIPT) Market”
The Europe
Non-Invasive Prenatal Testing (NIPT) Market is segmented into product, test
type, application, end user, country distribution, and company.
Based on the Application,
Trisomy emerged as the fastest growing segment in the Europe Non-Invasive
Prenatal Testing (NIPT) Market during the forecast period. Trisomy, a genetic
condition caused by an extra chromosome, includes disorders such as Down
syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome
(trisomy 13). NIPT is increasingly being used to screen for these conditions
due to its high accuracy and non-invasive nature, making it a preferred choice
for expectant mothers. The growing demand for trisomy screening can be
attributed to the rising awareness of genetic conditions and the importance of
early detection. With NIPT offering a safer and more accurate alternative to
traditional invasive tests, such as amniocentesis, expectant parents are more
inclined to opt for this non-invasive screening method. As healthcare systems
across Europe integrate NIPT into standard prenatal care, trisomy screening has
become a key focus.
Based
on the Country, United Kingdom emerged as the fastest growing country in the Europe
Non-Invasive Prenatal Testing (NIPT) Market during the forecast period. The rapid growth in the UK’s
NIPT market can be attributed to the country’s strong healthcare infrastructure
and increasing adoption of advanced prenatal screening technologies. NIPT has
become a widely accepted option for expectant mothers due to its high accuracy
in detecting genetic conditions like trisomy, along with its non-invasive
nature, which poses no risk to the pregnancy. The UK has made significant
strides in integrating NIPT into standard prenatal care, supported by national
health services and private healthcare providers offering these tests. The
country’s public awareness campaigns about the benefits of NIPT have led to a
rising demand for these services, especially in urban areas where access to
advanced healthcare is more readily available.
Major
companies operating in Europe Non-Invasive Prenatal Testing (NIPT) Market are:
- F.
Hoffmann-La Roche Ltd.
- Eurofins
LifeCodexx GmbH
- Yourgene
Health plc
- Centogene
N.V.
- QIAGEN
N.V.
- Eluthia
GmbH
- Life
Genomics AB
- TATAA
Biocenter AB
- Genoma
SA
- Synlab
International GmbH
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Europe Non-Invasive Prenatal Testing
(NIPT) Market is expanding due to the growing emphasis on personalized
healthcare and precision medicine in prenatal care. As genetic testing
technologies evolve, healthcare providers are increasingly focused on offering
tailored, patient-centric solutions that meet the specific needs of expectant
mothers. The shift towards personalized care, which allows for more accurate
risk assessments and informed decision-making, is driving the adoption of NIPT.
This trend is further supported by the rise in demand for non-invasive
procedures that ensure both the safety of the mother and the baby. Integration
of NIPT into personalized healthcare practices is contributing to the market's
growth.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Europe Non-Invasive
Prenatal Testing (NIPT) Market By Product (Consumables, Instruments), By Test
Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Application
(Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic
Laboratories, Hospitals, Others), By Country, Competition, Forecast and
Opportunities, 2020-2030F”, has evaluated the future growth potential of Europe
Non-Invasive Prenatal Testing (NIPT) Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and opportunities
in Europe Non-Invasive Prenatal Testing (NIPT) Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com